The promises of low dose IL-2 therapy for autoimmune and inflammatory diseases - 2017

Speaker Bio

David Klatzmann received his MD and PhD from the Pierre & Marie Curie Medical School, Paris (France). He is Professor of Immunology and Chairman of the Inflammation-Immunopathology-Biotherapy Department at the Pierre & Marie Curie Medical school, Sorbonne University.

His research interests are in translational Immunology, with a special focus on TReg cells. He and his group pioneered low-dose IL-2 immunotherapies.

He his the coordinator of the DIABIL-2 European consortium investigating low-dose IL-2  in type-1 diabetes.

www.diabil-2.eu

No RSVP Required
Refreshments from 3pm
Seminar starts 3.30pm